Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX – Free Report) – Equities researchers at Zacks Research issued their FY2026 earnings per share (EPS) estimates for Biodexa Pharmaceuticals in a research report issued to clients and investors on Monday, March 30th. Zacks Research analyst D. Bautz forecasts that the company will post earnings per share of $0.00 for the year. The consensus estimate for Biodexa Pharmaceuticals’ current full-year earnings is ($1.25) per share. Zacks Research also issued estimates for Biodexa Pharmaceuticals’ FY2027 earnings at $0.00 EPS.
BDRX has been the subject of several other reports. Weiss Ratings restated a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a report on Monday, December 29th. Wall Street Zen lowered shares of Biodexa Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday. One analyst has rated the stock with a Sell rating, According to MarketBeat, Biodexa Pharmaceuticals currently has a consensus rating of “Sell”.
Biodexa Pharmaceuticals Stock Performance
Shares of NASDAQ BDRX opened at $0.87 on Wednesday. Biodexa Pharmaceuticals has a one year low of $0.60 and a one year high of $19.30. The business has a 50-day moving average price of $1.13 and a two-hundred day moving average price of $3.77.
Biodexa Pharmaceuticals shares are set to reverse split before the market opens on Monday, April 6th. The 1-5 reverse split was announced on Wednesday, March 18th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, April 3rd.
Biodexa Pharmaceuticals (NASDAQ:BDRX – Get Free Report) last issued its quarterly earnings results on Friday, March 27th. The company reported $0.70 earnings per share for the quarter.
Institutional Investors Weigh In On Biodexa Pharmaceuticals
A hedge fund recently bought a new stake in Biodexa Pharmaceuticals stock. Sabby Management LLC purchased a new stake in shares of Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX – Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 190,658 shares of the company’s stock, valued at approximately $433,000. Biodexa Pharmaceuticals comprises approximately 0.6% of Sabby Management LLC’s holdings, making the stock its 10th biggest position. Sabby Management LLC owned approximately 28.04% of Biodexa Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 17.51% of the stock is currently owned by institutional investors.
About Biodexa Pharmaceuticals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.
Further Reading
Receive News & Ratings for Biodexa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodexa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
